Improving Fertility Through Science

OvaScience Leadership

Management

Michelle Dipp, M.D., Ph.D. — Chief Executive Officer and Co-Founder

Dr. Dipp is the founding Chief Executive Officer of OvaScience and serves on the Board of Directors. Dr. Dipp is also a Founder and Partner of Longwood Fund, which founds and invests in healthcare companies such as Alnara (acquired by Eli Lilly) and Verastem. Previously, Dr. Dipp was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior, she was Vice President of Corporate Development at Sirtris, where she led the successful acquisition of Sirtris by GSK for $720 million. Before joining Sirtris as a founding employee, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board, the Beth Israel Deaconess Medical Center Board of Trustees, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board.

Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.

Top of Page

Arthur Tzianabos, Ph.D. — Chief Scientific Officer

Dr. Tzianabos brings to OvaScience more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. He joins OvaScience from Shire, where he most recently served as Senior Vice President and Head, Research and Early Development. During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire?s acquisition of Transkaryotic Therapies, Inc. in 2005. Prior to Shire, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women?s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development. During his time at Harvard, he served as a consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. Dr. Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease, and was on the Board of Directors of bluebird bio and ArmaGen Technologies.

He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.

Top of Page

David Stern, M.B.A. — Global Commercial Operations

David L. Stern is the Executive Vice President of Global Commercial Operations at OvaScience. He is responsible for the global launch of the Company’s first potential new fertility treatment, AUGMENTSM, in 2014. AUGMENTSM is being developed to improve a women’s egg quality and therefore, increase the success of in vitro fertilization (IVF) by transferring mitochondria (energy packs) from her own egg precursor cells (EggPCSM) to her mature egg during IVF. OvaScience is a global life sciences company focused on the discovery, development and commercialization of new fertility treatments. The Company’s patented technology is based on EggPCs, which are found in the outer layer of a women’s own ovaries.

Before joining OvaScience, Mr. Stern spent ten years at Merck Serono in positions of increasing responsibility. He was the Senior Vice President and Head of the Global Business Franchise for Fertility, responsible for the strategic development and growth of the Fertility portfolio worldwide. Merck Serono is a leader in fertility treatments that are marketed in over 105 countries around the world. Prior, Mr. Stern was the Executive Vice President, Endocrinology at EMD Serono in the United States, responsible for the commercial operations in the Fertility, HIV and Growth Hormone markets. Before joining Serono in 2003, he was the Director, Reproductive Marketing at Organon USA and was responsible for the contraceptive and fertility brands.

Mr. Stern has been involved in the biopharmaceutical industry for more than 20 years and has launched numerous women’s health and metabolic brands, both on the professional and consumer markets in a sales and marketing capacity. He is a member of the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine. He is an active speaker on biopharmaceutical  marketing.

Mr. Stern has a Masters in Business Administration with a concentration in International Marketing and Management from the F.W. Olin School of Business at Babson College. He also holds a Bachelors’ degree in Biology with a minor in Economics from Brandeis University.

Top of Page